Search

Meld. St. 28 (2014–2015) - White Paper on Medicinal Products

Correct use – better health

Medical devices

Medical devices range from simple bandages and spectacles, through implantable devices and equipment, to diagnose and screen, to sophisticated minimal invasive surgery equipment.

Norway invests NOK 240 million in global pandemic preparedness

Norway is increasing its support to the Pandemic Fund by NOK 240 million for the period 2025-2027. This will strengthen the global, regional and national readiness and response to new pandemics and severe cross-border disease outbreaks.

Vaccination of children and adolescents against COVID-19

A vaccine will be offered to children aged 5-11 if so requested by their parents or guardians. This vaccination is provided on a voluntary basis, and there is no general recommendation to vaccinate all children in this age group.

National Strategy against Antibiotic Resistance

The Norwegian National Strategy Against Antibiotic Resistance 2015-2020 lays out the Government’s goals for work over the coming years and the steps needed to achieve these.

Meld. St. 5 (2023–2024) - A Resilient Health Emergency Preparedness

Meld. St. 5 (2023–2024) Report to the Storting (white paper)

Revised National Budget: Boosting access to diabetes medications and reducing national insurance user fees

The government’s revised national budget contains proposals for individual grants for the diabetes medication Rybelsus and the rationing of Ozempic in pharmacies.

Meld. St. 34 (2015–2016) - Principles for priority setting in health care

Summary of a white paper on priority setting in the Norwegian health care sector

Summary of a report from a working group, November 2015: Severity of illness and priority setting in Norway

Marketing authorisation of medicinal products

A medicinal product may only be placed on the market in the European Economic Area (EEA) when a marketing authorisation has been issued. There are four procedures for marketing authorisation.